Key facts
- This page summarizes Laurie Stelzer's Form 4 filing for Mirati Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Aug 2023, 16:26.
Laurie Stelzer - 09 Aug 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 09 Aug 2023
- Net transaction value
- +$824,989
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2023, 16:26:35 UTC
- Prior SEC filing
- 12 Jun 2023
- Next SEC filing
- 27 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Moriarty, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laurie Stelzer filed Form 4 for Mirati Therapeutics, Inc. on 10 Aug 2023.
Change
- Previous filing in this sequence was filed on 12 Jun 2023.
- Current net transaction value: +$824,989.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRTX
transaction
Common Stock
Award
- Transaction value
- $824,989
- Shares
- +22,297
- Change %
- +28%
- Price
- $37.00
- Shares after
- 102,312
- Date
- 09 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date.